Marked left ventricular hypertrophy in children on tacrolimus (FK506) after orthotopic liver transplantation

American Journal of Cardiology

Volumn 81, Issue 10, 1998, Pages 1277-1280

  Chang, Ruey Kang R ^a   Alzona, Maria ^b   Alejos, Juan ^b   Jue, Kenneth ^b   McDiarmid, Suzanne V ^b  

^a UCLA MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; TACROLIMUS;

ADOLESCENT; ARTICLE; CARDIOTOXICITY; CASE REPORT; ECHOCARDIOGRAPHY; FEMALE; GRAFT REJECTION; HEART LEFT VENTRICLE HYPERTROPHY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL;

EID: 0032525090     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00126-X     Document Type: Article

References (9)

1. 1. The US Multicenter Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994;332:1110-1115.
2. 2. Pham SM, Kormos RL, Kawai A, Murali S, Hattler BG, Demetris AJ, Griffith BP. Tacrolimus (FK506) in clinical cardiac transplantation: a five-year experience. Tranplant Proc 1996;28: 1002-1004.
3. 3. Busuttil RW, Holt CD. Tacrolimus (FK506) is superior to cyclosporine in liver transplantation. Transplant Proc 1996;29:534-538.
4. 4. Asante-Korang A, Boyle GJ, Webber SA, Miller SA, Fricker FJ. Experience of FK506 immune suppression in pediatric heart transplantation: a study of long-term adverse effects. J Heart Lung Transplant 1996:415-422.
5. 5. Nomoto S, Fujiwara H, Ban T, Ohara K. Cardiotoxicity of long-term intravenous adminstration of FK506 in rabbits: dose relationship and recovery after discontinuance. Transplant Proc 1994;26:855-857.
6. 6. Atkison P, Joubert G, Barron A, Grant D, Paradis K, Seidman E, Wall W, Rosenberg H, Howard J, Williams S, Stiller C. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. Lancet 1995:345:894-896.
7. 7. Chung SJ. Formulas predicting the percentile of heart weights by body weight in subjects from birth to 19 years of age. Int J Biomed Comput 1990;26: 257-269.
8. 8. Ohara K, Billington T, James RW, Dean GA, Nishiyama M, Noguchi H. Toxicologic evaluation of FK506. Transplant Proc 1990;22(suppl. 1):83-86.
9. 9. Werner JC, Sicard RE, Hansen TWR, Solomon E, Cowett RM, Oh W. Hypertrophic cardiomyopathy associated with dexamethasone therapy for bronchopulmonary dysplasia. J Pediatr 1992;28: 286-291.